Adaptive Biotechnologies (NASDAQ:ADPT) Announces Earnings Results, Beats Expectations By $0.12 EPS

Key Points

• Adaptive reported quarterly EPS of $0.02, beating analysts’ estimate of a $0.10 loss by $0.12. Revenue was $83.9 million, above the $71.57 million consensus estimate, though the article’s earnings summary says revenue declined 10.7% year over year.
• Management highlighted strong MRD business momentum, including 46% growth in clinical testing volume and 55% growth in pharma sequencing revenue excluding milestones, and raised 2026 MRD revenue guidance to $276 million–$286 million.
• More frequent Medicare testing is pressuring realized prices, and expanded coverage remains uncertain. The company does not expect full-year GAAP net income or positive EPS.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) released its earnings results on Wednesday. The company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.12, FiscalAI reports. The company had revenue of $83.90 million during the quarter, compared to analysts' expectations of $71.57 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies's revenue for the quarter was down 10.7% on a year-over-year basis. During the same period last year, the business earned $0.06 EPS.

Here are the key takeaways from Adaptive Biotechnologies' conference call:

• Adaptive reported Q3 revenue of $83.9 million, up 39%, and MRD revenue growth of 44% excluding prior-year milestones. It generated $14.3 million in adjusted EBITDA and $8 million in free cash flow, and raised its 2026 MRD revenue guidance to $276 million–$286 million.
• Clinical testing volume grew 46% year over year to nearly 40,000 clonoSEQ tests, with growth across reimbursed indications. Blood-based and community testing also expanded; management said updated myeloma guidelines and a new definition of cure could further support adoption, though those benefits remain prospective.
• MRD pharma sequencing revenue grew 55% year over year excluding milestones, while the study portfolio reached 191 active studies and backlog rose 34% to about $270 million. Management expects approximately 25% full-year pharma sequencing growth, but noted that quarterly revenue and milestone timing can be lumpy.
• More frequent Medicare testing beyond the existing four-test episode bundle pressured realized ASP, particularly in multiple myeloma. Adaptive has submitted for an additional maintenance-testing bundle and is in discussions with MolDX, but the timing and terms of any expanded coverage are uncertain; the company also said it does not expect full-year GAAP net income or positive EPS.
• Adaptive said it remains on track to announce a path forward for separating its Immune Medicine business by year end. The segment recognized a Pfizer milestone after delivering rheumatoid arthritis data, but management did not provide details on the separation outcome.

Adaptive Biotechnologies Trading Up 3.5%

Shares of Adaptive Biotechnologies stock traded up $0.91 on Wednesday, reaching $26.71. 2,326,040 shares of the stock were exchanged, compared to its average volume of 1,999,355. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies has a twelve month low of $12.00 and a twelve month high of $30.74. The business has a 50 day moving average price of $26.37 and a two-hundred day moving average price of $19.76.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Francis Lo sold 115,406 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $28.06, for a total transaction of $3,238,292.36. Following the completion of the sale, the insider directly owned 220,867 shares in the company, valued at approximately $6,197,528.02. The trade was a 34.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad Robins sold 321,324 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,050,763 shares of company stock worth $26,806,633 in the last quarter. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ADPT. Morgan Stanley raised their price target on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an "equal weight" rating in a report on Monday, October 12th. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, October 1st. TD Cowen boosted their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $30.06.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation NASDAQ: ADPT is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive's products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.